Ernexa Therapeutics Inc. (ERNA) - 10-K Summary
Business Context and Reporting Period
Company: Ernexa Therapeutics Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Ernexa is a preclinical-stage synthetic allogeneic iMSC (induced pluripotent stem cell-derived mesenchymal stem cell) therapy company. Its mission is to develop scalable, off-the-shelf cell therapies for cancer and autoimmune diseases.
Key Assets: The company relies heavily on an exclusive license from Factor Bioscience Limited (Factor L&C Agreement) for its core technology. Its lead product candidate, ERNA-101 (IL-7 and IL-15-secreting iMSCs), targets platinum-resistant ovarian cancer. A second candidate, ERNA-201, targets autoimmune disorders like rheumatoid arthritis.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Revenue | $0 | $582 |
| Net Loss | $(14,084) | $(44,539) |
| Operating Expenses | $9,319 | $16,160 |
| Cash and Cash Equivalents (Dec 31, 2025) | $1,884 | $1,729 |
| Accumulated Deficit | $(245,636) | $(231,536) |
| Stockholders' Equity | $2,401 | $1,701 |
Cash Flow: Net cash used in operating activities was $7.0 million in 2025, a significant improvement from $15.8 million in 2024. Financing activities provided $7.2 million in 2025, primarily from a private placement.
Material Changes vs. Prior Period
- Revenue Cessation: Revenue dropped to zero in 2025. In 2024, the company recognized $0.6 million from a customer contract that was assigned to Factor Bioscience in September 2024. No further performance obligations remain under that contract.
- Reduced Net Loss: The net loss decreased by approximately $30.5 million (68%) compared to 2024. This was driven by a $22.4 million loss on extinguishment of debt in 2024 (related to convertible note exchanges) which did not recur in 2025.
- Operating Expense Reduction: Total operating expenses decreased by $6.8 million. General and Administrative (G&A) expenses fell by $8.0 million, largely due to a $5.0 million reduction in occupancy expenses following the termination of a Somerville sublease in August 2024.
- Forward Sales Contract Expense: In 2025, the company recognized a $5.8 million non-cash expense related to a forward sales contract for a private placement, as the fair value of shares to be issued exceeded the proceeds.
- Debt Extinguishment Gain: In 2025, the company recognized a $0.8 million gain on extinguishment of debt for liabilities deemed time-barred under state statutes of limitation.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Milestones:
- ERNA-101: Following a successful pre-IND meeting with the FDA in Q4 2025, the company expects to complete IND-enabling studies and submit an IND in 2026, with a Phase I investigator-sponsored clinical trial targeted for the second half of 2026.
- Japan Expansion: Accepted into the Japan External Trade Organization acceleration program for market-entry guidance.
Capital Resources and Liquidity:
- Going Concern: The filing includes a "substantial doubt" warning regarding the company's ability to continue as a going concern based on cash balances as of December 31, 2025 ($1.9 million).
- Subsequent Financing: On February 10, 2026, the company completed a public offering raising approximately $9.6 million in net proceeds. This increased stockholders' equity to over $2.5 million, satisfying Nasdaq's Stockholders' Equity Rule.
Key Risks:
- Nasdaq Compliance: While equity requirements are now met, the stock price has traded below $1.00 since February 3, 2026. Failure to maintain the $1.00 bid price for 10 consecutive business days after a 30-day notice could lead to delisting, especially given a recent reverse stock split.
- Intellectual Property: The business is substantially dependent on the Factor L&C Agreement. Termination of this license would materially harm operations.
- Capital Needs: The company requires substantial additional capital to fund operations and clinical trials. Failure to raise capital could force a reduction in operations or cessation.
Unusual Items:
- Accountant Change: The company dismissed Grant Thornton LLP on June 30, 2025, and engaged Haskell & White LLP effective July 1, 2025.
- Executive Compensation: In March 2026, the Compensation Committee approved salary increases and discretionary bonuses for the CEO and SVP of Finance.
Investor Verification Checklist
- Verify Liquidity Post-Filing: Confirm the impact of the February 2026 public offering ($9.6M net proceeds) on the company's runway and ability to fund the 2026 IND submission and Phase I trial.
- Nasdaq Bid Price Status: Monitor the stock price closely to ensure it meets the $1.00 minimum bid price requirement to avoid delisting proceedings.
- Factor License Stability: Review the terms of the Factor L&C Agreement to understand termination risks and the company's exposure if the license is lost.
- Forward Sales Contract Accounting: Understand the $5.8 million non-cash expense recognized in 2025 and its impact on the reported net loss versus cash burn.
- Going Concern Assessment: Evaluate management's plan to secure future funding beyond the February 2026 offering, given the substantial accumulated deficit of $245.6 million.